Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study
A subgroup of GBM patients responds to BevCT up to three times in the recurrent setting, and these repeated responders exhibit prolonged survival. No definitive prognostic variables or histopathological features were found in this study. Further investigation into the downregulation of HILPDA and IGF2, along with high AGT promoter methylation levels and other potential predictive biomarkers, is warranted to better understand the mechanisms underlying repeated BevCT response.
Authors
- Thomas Urup (ORCID: https://orcid.org/0000-0003-3072-3317)
- Hans Skovgaard Poulsen (ORCID: https://orcid.org/0000-0002-9801-5387)
- Signe Regner Michaelsen (ORCID: https://orcid.org/0000-0001-9047-6384)
- Maya Jeje Schuang Lü (ORCID: https://orcid.org/0000-0002-4839-4040)
- Linea Cecilie Melchior (ORCID: https://orcid.org/0000-0001-7061-8859)
- David Scheie (ORCID: https://orcid.org/0000-0002-8692-1198)
- Ulrik Lassen (ORCID: https://orcid.org/0000-0002-3865-4574)
- Alessio Locallo (ORCID: https://orcid.org/0000-0003-0977-9586)
- Joachim Weischenfeldt
- Christina Schjellerup Eickhart-Dalbøge
Institutions
- University of Copenhagen (DK)
- Region Zealand (DK)
- Rigshospitalet (DK)
- North Denmark Region (DK)
- Zealand University Hospital (DK)
- Danish Breast Cancer Cooperative Group (DK)
- Danish Cancer Society (DK)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1007/s11060-025-05162-2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00